| Autor: |
Necchi, A. Sonpavde, G. Lo Vullo, S. Giardiello, D. Bamias, A. Crabb, S.J. Harshman, L.C. Bellmunt, J. De Giorgi, U. Sternberg, C.N. Cerbone, L. Ladoire, S. Wong, Y.-N. Yu, E.Y. Chowdhury, S. Niegisch, G. Srinivas, S. Vaishampayan, U.N. Pal, S.K. Agarwal, N. Alva, A. Baniel, J. Golshayan, A.-R. Morales-Barrera, R. Bowles, D.W. Milowsky, M.I. Theodore, C. Berthold, D.R. Daugaard, G. Sridhar, S.S. Powles, T. Rosenberg, J.E. Galsky, M.D. Mariani, L. RISC Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Popis: |
Background The available prognostic models for overall survival (OS) in patients with metastatic urothelial carcinoma (UC) have been derived from clinical trial populations of cisplatin-treated patients. Objective To develop a new model based on real-world patients. Design, setting, and participants Individual patient-level data from 29 centers were collected, including metastatic UC and first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011. Intervention First-line, platinum-based, combination chemotherapy. Outcome measurements and statistical analysis The population was randomly split into a development and a validation cohort. Generalized boosted regression modelling was used to screen out irrelevant variables and address multivariable analyses. Two nomograms were built to estimate OS probability, the first based on baseline factors and platinum agent, the second incorporating objective response (OR). The performance of the above nomograms and that of other available models was assessed. We plotted decision curves to evaluate the clinical usefulness of the two nomograms. Results and limitations A total of 1020 patients were analyzed (development: 687, validation: 333). In a platinum-stratified Cox model, significant variables for OS were performance status (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
